Anti‐sclerostin antibodies for the treatment of osteoporosis
References
Additional references
Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid‐induced osteoporosis. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD001347.pub2]
Bouillon R, Burckhardt P, Christiansen C, Fleisch HA, Fujita T, Gennari C, et al. Consensus development conference: prophylaxis and treatment of osteoporosis. American Journal of Medicine 1991;90:107‐10.
Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clinical and Experimental Rheumatology 2005;23(Suppl 39):S14‐8.
Burge R, Dawson‐Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025. Journal of Bone and Mineral Research 2007;22(3):465‐75.
Chapurlat, R. Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?. Joint, Bone, Spine 2016;83(3):254‐6.
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Eriksen EF, Robins DA. Teriparatide: a bone formation treatment for osteoporosis. Drugs of Today (Barcelona, Spain:1998) 2004;40(11):935‐48.
FDA approved drug products web site. www.accessdata.fda.gov/scripts/cder/daf/ (accessed on 29‐3‐2017).
Fu R, Holmer HK. Change score or follow‐up score? Empirical evaluation of the impact of choice of mean difference estimates. Research White Paper. Agency for Healthcare Research and Quality. Vol. Available from www.effectivehealthcare.ahrq.gov/reports/final.cfm, Portland (OR): Oregon Evidence‐based Practice Center, 2015.
Ghogomu EAT, Maxwell LJ, Buchbinder R, Rader T, Pardo PJ, Johnston RV, et al. Editorial Board of the Cochrane Musculoskeletal, Group. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta‐analyses. Journal of Rheumatology 2014;41(2):194‐205.
Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf‐1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. Journal of Biological Chemistry 2010;285(51):40135‐47.
Helmes E, Hodsman A, Lazowski D, Bhardwaj A, Crilly R, Nichol P, et al. A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 1995;50(2):M91‐8.
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of osteoporosis 2013;8(1‐2):136.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Homik J, Suarez‐Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid‐induced osteoporosis. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000952]
Iñiguez‐Ariza NM, Clarke BL. Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas 2015;82(2):245‐255.
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis international 2006;17(12):1726‐33.
Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1984;9(8):1137‐41.
Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nature Reviews Rheumatology 2011;7(11):631‐8.
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 2005;280(20):19883‐7.
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research 2009;24(4):578‐88.
Lips P, Agnusdei D, Caulin F, Cooper C, Johnell O, Kanis J, et al. The development of a European questionnaire for quality of life in patients with vertebral osteoporosis. Scandinavian Journal of Rheumatology 1996;25 Suppl 103:84‐5.
Lydick E, Zimmerman SI, Yawn B, Love B, Kleerekoper M, Ross P, et al. Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). Journal of Bone and Mineral Research 1997;12(3):456‐63.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez‐Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. New England Journal of Medicine 2014;370(5):412‐20.
McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single‐and multiple‐dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. Journal of Bone and Mineral Research 2014;29(4):935‐43.
National Osteoporosis Foundation. America’s bone health:The state of osteoporosis and low bone mass in our nation.Washington, DC, USA. America’s bone health:The state of osteoporosis and low bone mass in our nation. The Foundation, 2002.
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research 2011;26(1):19‐26.
Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, et al. A randomized, double‐blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. Journal of Bone and Mineral Research 2015;30(2):216‐24.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Semënov M, Tamai K, Xi H. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. Journal of Biological Chemistry 2005;280(29):26770‐5.
Silverman SL, Mason J, Greenwald M. The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid self‐assessment measure of quality of life in osteoporosis. Journal of Bone and Mineral Research 1993;8:S343.
Silverman S, Minshall M. Principal component factor analysis of quality of life in patients with osteoporotic vertebral fractures. Journal of Bone and Mineral Research 1997;12:F553.
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Tarride J‐E, Hopkins RB, Leslie WD, Morin S, Adachi JD, Papaioannou A, et al. The burden of illness of osteoporosis in Canada. Osteoporosis International 2012;23(11):2591–600.
Tella SH, Gallagher JC. Biological agents in management of osteoporosis. European Journal of Clinical Pharmacology 2014;70(11):1291‐301.
Van Bezooijen RL, Roelen BAJ, Visser A, Van Der Wee‐pals L, De Wilt E, Karperien M, et al. Sclerostin is an osteocyte‐expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 2004;199(6):805‐14.
Ware JE, Snow KK, Kosinski M, Gandek B. SF‐36 Health Survey: Manual and Interpretation Guide. Boston (MA): Health Insuitute, New England Medical Center, 1993.
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series. 1994.
Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL‐dependent pathway. PLoS One 2011;6(10):e25900.
Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22(23):6267‐76.
